Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-304: tarlatamab versus standard-of-care chemotherapy in relapsed small cell lung cancer
2022-502669-14-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Dec 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 31
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing Tarlatamab with Standard of care chemotherapy (2 arms). Primary endpoint: Overall survival. Planned start Dec 2023; status: authorised.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2022-502669-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502669-14-00.